Genetic profiling in inflammatory bowel disease: From association to bedside

Gastroenterology

Volumn 141, Issue 5, 2011, Pages 1566-1571.e1

  Van Limbergen, Johan ^a,b,c   Philpott, Dana ^b   Griffiths, Anne M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATG16L1 PROTEIN; BIOLOGICAL MARKER; CASPASE RECRUITMENT DOMAIN PROTEIN 15; HISTONE DEACETYLASE 1; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 23 RECEPTOR; JANUS KINASE 2; MICRORNA; PROTEIN; STAT3 PROTEIN; TLE1 PROTEIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

AUTOPHAGY; COMPARATIVE STUDY; DISEASE COURSE; ENTERITIS; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETICS; GENOTYPE; HUMAN; ONCOGENE C MYC; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 80054852494     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.09.018     Document Type: Article

References (46)

1. Booth RA, Ansari MT, Loit E, et al. Assessment of thiopurine s-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011;154:814-823.
2. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-304.
3. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006;130:650-656.
4. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010;7:15-29.
5. Jürgens M, Mahachie JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011;9:421-427.e1.
6. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817-1826.e2.
7. Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125.
8. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-252.
9. Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet 2009;41:1335-1340.
10. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009;41:71-76.
11. Muise AM, Walters TD, Xu W, et al. The GTPase RAC1 is associated with ulcerative colitis. Gastroenterology 2011;141:633-641.
12. Renz H, von Mutius E, Brandtzaeg P, et al. Gene-environment interactions in chronic inflammatory disease. Nat Immunol 2011;12:273-277.
13. Gojobori T, Rossin EJ, Lage K, et al. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 2011;7:e1001273.
14. Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Annu Rev Genomics Human Genet 2009;10:89-116.
15. Adler J, Rangwalla SC, Dwamena BA, et al. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a metaanalysis. Am J Gastroenterol 2011;106:699-712.
16. Dideberg V, Kristjansdottir G, Milani L, et al. An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet 2007;16:3008-3016.
17. Pandey AK, Yang Y, Jiang Z, et al. NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog 2009;5:e1000500.
18. Krausgruber T, Blazek K, Smallie T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011;12:231-238.
19. Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases. Gut 2011 Feb 7 [Epub ahead of print].
20. Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011;140:1704-1712.e2.
21. Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011;43:17-19.
22. Janse M, Lamberts LE, Franke L, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL and CARD9. Hepatology 2011:53:1977-1985.
23. Figueroa C, Cleynen I, Franke A, et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype, but do not predict it. Results from the IBDchip European project. Gastroenterology 2010;138:S-678.
24. Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009;7:972-980.e2.
25. Dubinsky M, Kugathasan S, Kwon S, et al. A combination of genetic, clinical and immune markers predict the need for surgery in Crohn's disease. Gastroenterology 2011;140:S-153.
26. Lichtenstein GR, Targan SR, Dubinsky MC, et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflammatory Bowel Diseases 2011 Mar 9 [Epub ahead of print].
27. Georges M. The long and winding road from correlation to causation. Nat Genet 2011;43:180-181.
28. Nimmo ER, Phillips AM, Stevens C, et al. Analysis of protein-protein and gene-gene interactions implicates TLE1 as a critical modifier of NOD2 effect in Crohn's disease. Gastroenterology 2011;141:972-981.
29. Brest P, Lapaquette P, Souidi M, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet 2011;43:242-245.
30. Kobayashi K, Inohara N, Hernandez LD, et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002;416:194-199.
31. Kufer TA, Kremmer E, Banks DJ, et al. Role for erbin in bacterial activation of Nod2. Infect Immun 2006;74:3115-3124.
32. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010;11:55-62.
33. Barnich N, Hisamatsu T, Aguirre JE, et al. GRIM-19 interacts with nucleotide oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells. J Biol Chem 2005;280:19021-19026.
34. Damiano JS, Newman RM, Reed JC. Multiple roles of CLAN (caspase-associated recruitment domain, leucine-rich repeat, and NAIP CIIA HET-E, and TP1-containing protein) in the mammalian innate immune response. J Immunol 2004;173:6338-6345.
35. Plantinga TS, Crisan TO, Oosting M, et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut 2011;60:1229-1235.
36. Hsu YM. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol 2007;8:198-205.
37. Yeretssian G, Correa RG, Doiron K, et al. Non-apoptotic role of BID in inflammation and innate immunity. Nature 2011;474:96-99.
38. Momozawa Y, Mni M, Nakamura K, et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet 2011;43:43-47.
39. Wang K, Zhang H, Kugathasan S, et al. Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn disease. Am J Human Genet 2009;84:399-405.
40. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010;16:90-97.
41. Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:179-184.
42. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011;140:1720-1728.e3.
43. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009;361:2033-2045.
44. Begue B, Verdier J, Rieux-Laucat F, et al. Defective IL10 Signaling defining a subgroup of patients with inflammatory bowel disease. Am J Gastroenterol 2011;106:1544-1555.
45. Glocker EO, Frede N, Perro M, et al. Infant colitis: it's in the genes. Lancet 2010;376:1272.
46. Noguchi E, Homma Y, Kang X, et al. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol 2009;10:471-479.